Impact of HER2 status on clinicopathological characteristics and pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer-Reference-Cited by-同舟云学术

Impact of HER2 status on clinicopathological characteristics and pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer

Published:2024-04-24 Issue:2 Volume:206 Page:387-395
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Shi Yue,Lu Heng,Zhang Yiqi

Funder

Education Department Foundation of Liaoning Province of China

Youth Science Program of the First Affiliated Hospital of Jinzhou Medical University

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10549-024-07317-7.pdf

Reference31 articles.

1. Bianchini G, De Angelis C, Licata L, Gianni L (2022) Treatment landscape of triple-negative breast cancer—expanded options, evolving needs. Nat Rev Clin Oncol 19:91–113. https://doi.org/10.1038/s41571-021-00565-2

2. Corti C, Giugliano F, Nicolò E, Tarantino P, Criscitiello C, Curigliano G (2023) HER2-low breast cancer: a new subtype? Curr Treat Options Oncol 24:468–478. https://doi.org/10.1007/s11864-023-01068-1

3. Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical practice guideline focused update. Arch Pathol Lab Med 142:1364–1382. https://doi.org/10.5858/arpa.2018-0902-SA

4. Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E et al (2020) HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol 38:1951–1962. https://doi.org/10.1200/JCO.19.02488

5. Denkert C, Seither F, Schneeweiss A, Link T, Blohmer JU, Just M et al (2021) Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol 22:1151–1161. https://doi.org/10.1016/S1470-2045(21)00301-6